Bevacizumab, an anti-VEGF antibody, reverses VEGF-induced severe anemia and reduces mortality in tumor-bearing mice [22], indicating that VEGF may be a promising target for cancer-induced anemia treatment. This evidence concerns the gene VEGFA and anemia (phenotype).